Contents

Volume 80  Issue 11  |  ARD November 2021

Editorial
1367  What is the optimal target for a T2T approach in axial spondyloarthritis?
J Sieper, D Pododdumy

Heroes and pillars of rheumatology
1370  Clemens von Pirquet
C Scheinecker, D Kraft

Viewpoint
1373  Ultrasound definition of enthesis in spondyloarthritis and psoriatic arthritis: arrival or starting point?
E Filippucci, G Smerilli, A Di Matteo, W Grassi

Rheumatoid arthritis
1376  Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial

1385  Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis

1393  Abaracept is second to rituximab at risk of HbA1c reverse seroconversion in patients with rheumatic disease
M-H Chen, C-C Lee, M-H Chen, M-C Hou, C-Y Tsai, Y-H Huang

1400  Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study evaluating a randomised clinical trial

Psoriatic arthritis
1410  Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis.
Data from the EuroSpA collaboration

Spondyloarthritis
1436  Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

1449  Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results

1419  Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis

MORE CONTENTS ►
Contents

1445 Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
U Lindström, K Bengsson, T Olfsson, D Di Giuseppe, B Glintborg, H Forsblad-d'Elia, T H Jacobsson, J Askling

Systemic sclerosis
1453 Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis
A M Gaydosik, T Tabib, R Domsic, D Khazena, R Lufyatis, P Fuschiotti

Myositis
1461 Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies
W I Che, H Westerlund, I E Lundberg, K Hellgren, R Kojá-Hallkeda, M Holmqvist

Vasculitis
1467 Treatment failure in giant cell arteritis
S H Unizony, M Baso, J Han, Y Luder, A Pavlov, J H Stone

1475 Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis
C Ponte, S Monti, C A Scire, P Delvino, N Kholmelnitski, A Milanesi, V Teixeira, F Brandolino, F Saraiva, C Montecucco, J E Fonseca, W A Schmidt, R A Luymami

Crystal arthropathies
1483 Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan
R Kato, A Nakajima, H Horuchi, H Yamanaoka

Letters
1491 Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis
S Takashashi, Y Kaneko, T Takeuchi

1493 Joint tenderness and ultrasound inflammation in DMARD-naïve patients with early rheumatoid arthritis

1494 Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis
M Akhar, L MacDonald, L A N Crowe, K Carlberg, M Kurewiska-Skolarska, P L Stahl, S J B Snelling, I B McNees, N L Miller

1497 Effects of face masks on oxygen saturation and functional measures in patients with connective tissue disorder-associated interstitial lung disease
A Vijayan, S Ahmed, S Joseph, A Sukumaran, S Ahmed, P Shenoy

1498 Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group
F Ursini, P Rusciniti, S D’Angelo, F Cascapaglia, R De Angelis, C Campochiaro, F Caso, M De Santis, I Di Cela, S Parisi, V Raimondo, G Abignano, L Costa, J Carelli, L Dagnino, A Iagnocco, F Lamone, R Meliconi, R Ciaconcelli, C Ferri

1501 Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan
Y Kanno, K Takase-Minojigishi, N Tsuchida, L Hirozaka, Y Kamishita, R Yoshimi, H Nakajima

Electronic pages

1472 Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al
L C Berkhout, M J J Ami, G J Wobbe, T Rispens

1473 Response to: ‘Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al’ by Berkhout et al
Y Tanaka, K Ohta, T Takeuchi

1474 Gut-derived CD8+ tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients
G Gugino, A Rizzo, D Mauro, F Macaluso, F Ciccia

1475 Response to: ‘Gut-derived CD8+ tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients’ by Gugino et al
Z Qaishom, E Gracey, YC Yao, R D Human

1476 Gut microbiome in rheumatic diseases
S Moiseev, V Rameev, E Karovaikina, L Lysenko (Kozlovskaya)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>e177</td>
<td>The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus</td>
<td>S-X Zhang, J Wang, J-W Chen, M-X Zhang, Y-F Zhang, F-Y Hu, Z-Q Lv, C Gao, Y-F Li, X-F Li</td>
</tr>
<tr>
<td>e178</td>
<td>Response to: ‘The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus’ by Zhang et al and the phylogeny of a candidate pathobiont in lupus nephritis</td>
<td>G J Silverman, D F Azzouz</td>
</tr>
<tr>
<td>e180</td>
<td>Association between osteoporosis and statins therapy</td>
<td>S-W Lai</td>
</tr>
<tr>
<td>e181</td>
<td>Response to: ‘Association between osteoporosis and statins therapy’ by Lai</td>
<td>M Leutner, C Mazhold, L Bellach, C Deischinger, J Harreiter, S Thurner, P Klimmek, A Katazky-Willer</td>
</tr>
<tr>
<td>e182</td>
<td>Anti-Ku antibodies: important points to consider</td>
<td>M Mahler, M Satoh, M J Fritzler</td>
</tr>
<tr>
<td>e183</td>
<td>Response to: ‘Anti-Ku antibodies: important points to consider’ by Mahler et al</td>
<td>M Ogawa-Momohara, Y Muro, M Akiyama</td>
</tr>
<tr>
<td>e184</td>
<td>Temporal ultrasound for monitoring tocilizumab treatment in giant cell arteritis: seeing beyond serum markers?</td>
<td>G Evangelatos, G E Fragoulis, A Iliopoulos</td>
</tr>
<tr>
<td>e185</td>
<td>Involvement of industry in review articles published in Annals of the Rheumatic Diseases</td>
<td>M Rudwaleit</td>
</tr>
<tr>
<td>e186</td>
<td>Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double blind, placebo-controlled, dose-ranging study</td>
<td>M Rudwaleit</td>
</tr>
<tr>
<td>e187</td>
<td>Correction: Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis</td>
<td>M Rudwaleit</td>
</tr>
</tbody>
</table>